M
Martha Q. Lacy
Researcher at Mayo Clinic
Publications - 771
Citations - 29738
Martha Q. Lacy is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Transplantation. The author has an hindex of 87, co-authored 713 publications receiving 25974 citations. Previous affiliations of Martha Q. Lacy include Kyungpook National University Hospital & University of Rochester.
Papers
More filters
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús F. San Miguel,Jesús F. San Miguel,Katja Weisel,Philippe Moreau,Martha Q. Lacy,Kijoung Song,Michel Delforge,Lionel Karlin,Hartmut Goldschmidt,Anne Banos,Albert Oriol,Adrian Alegre,Christopher T. Chen,Michele Cavo,Laurent Garderet,Valentina Ivanova,Joaquin Martinez-Lopez,Andrew R. Belch,Antonio Palumbo,Steve Schey,Pieter Sonneveld,Xiaoyan Yu,Lars Sternas,Christian Jacques,Mohamed H. Zaki,Meletios A. Dimopoulos +25 more
TL;DR: Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients withRefractory or relapsed and refractory multiple myeloma.
Journal ArticleDOI
POEMS syndrome: definitions and long-term outcome.
Angela Dispenzieri,Robert A. Kyle,Martha Q. Lacy,S. Vincent Rajkumar,Terry M. Therneau,Dirk R. Larson,Philip R. Greipp,Thomas E. Witzig,Rita Basu,Guillermo A. Suarez,Rafael Fonseca,John A. Lust,Morie A. Gertz +12 more
TL;DR: The median survival of patients with POEMS syndrome is 165 months, independent of the number of syndrome features, bone lesions, or plasma cells at diagnosis.
Journal ArticleDOI
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji Kumar,Joseph R. Mikhael,Francis K. Buadi,David Dingli,Angela Dispenzieri,Rafael Fonseca,Morie A. Gertz,Philip R. Greipp,Suzanne R. Hayman,Robert A. Kyle,Martha Q. Lacy,John A. Lust,Craig B. Reeder,Vivek Roy,Stephen J. Russell,Kristen Detweiler Short,A. Keith Stewart,Thomas E. Witzig,Steven R. Zeldenrust,Robert J. Dalton,S. Vincent Rajkumar,P. Leif Bergsagel +21 more
TL;DR: This set of recommendations represents the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence.
Journal ArticleDOI
Clinical course of patients with relapsed multiple myeloma.
Shaji Kumar,Terry M. Therneau,Morie A. Gertz,Martha Q. Lacy,Angela Dispenzieri,S. Vincent Rajkumar,Rafael Fonseca,Thomas E. Witzig,John A. Lust,Dirk R. Larson,Robert A. Kyle,Philip R. Greipp +11 more
TL;DR: This study revealed decreasing response duration with increasing number of salvage regimens, probably reflecting acquired drug resistance and an increasing proliferative rate of the myeloma cells.
Journal ArticleDOI
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Angela Dispenzieri,Morie A. Gertz,Robert A. Kyle,Martha Q. Lacy,Mary F. Burritt,Terry M. Therneau,Joseph P. McConnell,Mark R. Litzow,Dennis A. Gastineau,Ayalew Tefferi,David J. Inwards,Ivana N. Micallef,Stephen M. Ansell,Luis F. Porrata,Michelle A. Elliott,William J. Hogan,S. Vincent Rajkumar,Rafael Fonseca,Philip R. Greipp,Thomas E. Witzig,John A. Lust,Steven R. Zeldenrust,Denise S. Snow,Susan R. Hayman,Christopher G.A. McGregor,Allan S. Jaffe +25 more
TL;DR: It is reported that circulating cardiac biomarkers are the best predictors of survival outside of the transplantation setting and whether cardiac troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in transplant recipients.